News

December 6, 2019December 6, 2019

CurePSP Grant to FTD Disorders Registry Intended to Educate, Raise Awareness About Neurodegenerative Disorders

News

With a $100,000 grant, the FTD Disorders Registry has received a boost from CurePSP, a nonprofit organization working to enhance awareness, education and care for prime-of-life neurodegenerative diseases. Launched in ... Read more

December 4, 2019

‘Jumping Genes’ Identified as Possible Cause of ALS, Linked to TDP-43 Protein Accumulation

News

A new study identified a group of sporadic amyotrophic lateral sclerosis (ALS) patients whose disease may arise from a group of “jumping genes” unleashed when TDP-43 protein accumulates in ... Read more

December 4, 2019December 5, 2019

HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases

News

Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s ... Read more

December 3, 2019December 3, 2019

Washington State Beats University of Washington in ALS Fundraising Challenge for Team Gleason

News

When intrastate rivals University of Washington (UW) and Washington State University (WSU) met Nov. 29 for the storied Boeing Apple Cup Series, the battle wasn’t just about football — ... Read more

December 2, 2019December 2, 2019

Anti-Inflammatory Delays ALS Symptoms and Progression in Mouse Model, Study Reports

News

Cromolyn sodium — a U.S. Food and Drug Administration (FDA)-approved anti-inflammatory medication — delayed disease onset and prevented motor neuron degeneration and loss in a mouse model of amyotrophic ... Read more

November 27, 2019November 27, 2019

1st ALS Patient Enters Phase 3 Study of Oral Edaravone in Slowing Disability

News

Mitsubishi Tanabe Pharma America (MTPA) has enrolled a first patient in a Phase 3 clinical trial of an oral suspension formulation of edaravone in treating amyotrophic lateral sclerosis (ALS). An intravenous ... Read more

November 26, 2019November 26, 2019

Exservan, Riluzole in Dissolving Oral Film Form, Approved by FDA

News

A dissolving oral film form of riluzole, called Exservan and able to be taken by amyotrophic lateral sclerosis (ALS) patients without a need for water, has been approved by the U.S. ... Read more

November 25, 2019November 25, 2019

Phase 2 Trial Data on NurOwn Therapy, Supporting Safety And Early Efficacy, Published

News

NurOwn showed a good safety profile, as well as potential efficacy in a Phase 2 clinical trial that included people with rapidly progressing amyotrophic lateral sclerosis (ALS). Trial results, ... Read more

November 22, 2019November 22, 2019

$106M Weill Family Foundation Gift Opens Research Network to Advance Neuroscience

News

A $106 million Weill Family Foundation initiative will bring together interdisciplinary researchers and clinicians at three West Coast universities in hopes of finding new treatments for brain and nervous system ... Read more

November 21, 2019November 21, 2019

ALS Candidate AT-1501 Advances to Phase 2 Studies, Anelixis Therapeutics Announces

News

Anelixis Therapeutics has completed its Phase 1 clinical trial testing AT-1501, an investigational antibody, in healthy volunteers and eight amyotrophic lateral sclerosis (ALS) patients. The company also announced it has secured ... Read more

Pin It on Pinterest